Anticancer activity of combination targeted therapy using cetuximab plus vemurafenib for refractory BRAF (V600E)-mutant metastatic colorectal carcinoma.

Connolly, K; Brungs, D; Szeto, E; Epstein, R J

Connolly, K; Brungs, D; Szeto, E; Epstein, R J.

Afiliación

Connolly K; Department of Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital, and UNSW Clinical School, Sydney, Australia.
Brungs D; Department of Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital, and UNSW Clinical School, Sydney, Australia.
Szeto E; Department of Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital, and UNSW Clinical School, Sydney, Australia.
Epstein RJ; Department of Oncology, The Kinghorn Cancer Centre, St Vincent's Hospital, and UNSW Clinical School, Sydney, Australia.

Curr Oncol ; 21(1): e151-4, 2014 Feb.

Article en En | MEDLINE | ID: mdl-24523613

Palabras clave

Colorectal neoplasms; combination drug therapy; genomic profiling; personalized oncology; precision medicine

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Curr Oncol Año: 2014 Tipo del documento: Article País de afiliación: Australia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google